Nivolumab with ipilimumab for treating squamous cell carcinoma of the head and neck [ID1355]
Discontinued
Reference number: GID-TA10321
As you will be aware the Department for Health and Social Care has asked NICE to conduct an appraisal of nivolumab with ipilimumab for treating platinum-refractory squamous cell carcinoma of the head and neck.
For information, the company announced that Checkmate 714 did not meet its primary endpoints in the platinum-refractory cohort and will not be pursuing a marketing authorisation application in this indication at this time.
Therefore NICE has decided to suspend this appraisal from its current work programme.
As this appraisal has been referred, NICE will continue to monitor any development and will update interested parties if the situation changes.